Data Driven Dealmaking with Inpart Deal and Evaluate
Access webinar replay
Today’s biopharma dealmaking is driven by data.
Successful BD and S&E teams rely on having accurate information at their fingertips to inform decision making and accelerate their partnering, so it’s no surprise that digital technologies that deliver data to dealmakers add real value to top pharma organizations.
Panelists
In this webinar product leaders and partnering experts Ben Folwell of Evaluate and Echo Zhang of Inpart explain how their top pharma customers encouraged them to integrate their data and software solutions more deeply. In this webinar you’ll learn:
- How S&E teams use Inpart Deal and Evaluate to rapidly filter large volumes of data
- How to generate industry and market insights faster than commercial search engines
- How clients leverage ‘Extended Profiles’ to add enormous value to dealmaking operations
This webinar includes a full demonstration of the integration between Inpart Deal and Evaluate data as well as an opportunity to interact with solution experts to uncover the true added value of this digital collaboration.
Staying ahead of the curve in dealmaking is essential to partnering success. One key aspect of this is having access to accurate and insightful data to drive decision-making processes. This is where the powerful integration between Inpart and Evaluate comes into play, offering a comprehensive solution for clients in the biopharma space. By combining the capabilities of these two platforms, companies can streamline their deal-making processes, enhance their data-driven decision-making, and ultimately achieve better outcomes for their partnerships.
Deal + Evaluate = Powered-up partnering
Inpart Deal serves as a central hub for tracking and managing the dealmaking process. With a focus on modernizing and optimizing partnering, Deal provides a user-friendly interface that empowers industry teams to streamline their workflows, centralize data, and make informed decisions at every stage of the dealmaking process. By integrating with Evaluate, a leading provider of commercial intelligence and predictive analytics in the life sciences industry, Deal users gain access to a wealth of valuable data that enhances their ability to evaluate opportunities, assess risks, and drive successful deals.
The integration between Inpart Deal and Evaluate offers users a range of benefits, from quick access to company profiles and R&D projects, to in-depth insights on predicted launch dates, sales forecasts, and probability of technical and regulatory success. This comprehensive data allows users to efficiently evaluate potential partnerships, make informed decisions, and navigate the complex landscape of biopharma deal making with confidence. By leveraging this integrated solution, companies can accelerate their deal-making processes, identify strategic opportunities, and maximize the value of their partnerships.
Next-level partnering performance
For companies attending major partnering events such as BIO Europe or the BIO International Convention, the Inpart-Evaluate integration provides a valuable tool for preparing for meetings and evaluating potential partners. With quick access to company profiles, asset information, and predictive analytics, users will enter meetings fully informed, confident, and ready to engage in meaningful discussions. This level of preparation can make a significant difference in the success of partnership discussions and help companies make the most of their networking opportunities at industry events.
The ability to access Evaluate data directly within the Deal platform offers a seamless and efficient way for users to leverage valuable insights in their deal-making processes. Whether it's assessing company characteristics, evaluating assets at different development stages, or tracking upcoming milestones, the integrated solution provides a comprehensive set of tools to support users at every stage of the partnering process. By leveraging the combined strengths of Inpart and Evaluate, companies can enhance their deal-making capabilities, drive strategic partnerships, and achieve their business objectives more effectively.
With the ever-evolving landscape of the biopharma industry, having the right tools and insights at hand is essential for staying competitive and achieving sustainable growth. The Inpart Deal and Evaluate integration offers a valuable resource for companies looking to navigate this dynamic industry with confidence and precision.